The deal will aim to help the companies discover and develop respiratory and ophthalmology therapies.
Pieris shares rocketed by nearly 50 percent within three hours of the news of the deal dropping.
Pieris will be responsible for discovery research, and Genentech will be responsible for IND-enabling activities, clinical development and commercialization of those programs.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
